Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston
3
×
boston blog main
boston top stories
clinical trials
deals
life sciences
national blog main
alexion pharmaceuticals
autoimmune disorders
fda
national top stories
allosteric
alnylam pharmaceuticals
amyotrophic lateral sclerosis (als)
atlas venture
atopic dermatitis
boehringer ingelheim
brace pharma
cleva pharma
complement system
dicerna pharamceuticals
drug discovery
dupilumab
generalized myasthenia gravis
glaxosmithkline
hepatitis b
hepatitis b virus
hereditary transthyretin amyloidosis
hotspot therapeutics
immune-mediated necrotizing myopathy
investing
jonathan montagu
metabolic diseases
mrl ventures fund
patisiran
ra pharmaceuticals
rare disease drugs
rna interference
roche
What
disease
3
×
medicines
3
×
drug
pharma
pharmaceuticals
potential
address
adds
ago
allosteric
alternative
autoimmune
candidate
caught
causing
clinic
deal
dicerna
elusive
expensive
eye
gene
hepatitis
hotspot
intended
lead
molecules
new
path
pay
producing
protein
ra
research
roche
set
stakes
steer
stop
targets
Language
unset
Current search:
biotech
×
disease
×
boston
×
medicines
×
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma